UY31868A - Derivados de urea macrocíclicos y derivados de sulfamida como inhibidores de tafia - Google Patents

Derivados de urea macrocíclicos y derivados de sulfamida como inhibidores de tafia

Info

Publication number
UY31868A
UY31868A UY31868A UY31868A UY31868A UY 31868 A UY31868 A UY 31868A UY 31868 A UY31868 A UY 31868A UY 31868 A UY31868 A UY 31868A UY 31868 A UY31868 A UY 31868A
Authority
UY
Uruguay
Prior art keywords
derivatives
sulfamida
tafia inhibitors
inhibitors
macrocyclic urea
Prior art date
Application number
UY31868A
Other languages
English (en)
Spanish (es)
Inventor
Dr Michael Wagner
Dr Christopher Kallus
Dr Mark Broenstrup
Dr Andreas Evers
Dr Anja Globisch
Dr Herman Schreuder
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY31868A publication Critical patent/UY31868A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D273/00Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/01Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having one nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D267/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D273/00Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
UY31868A 2008-06-06 2009-06-04 Derivados de urea macrocíclicos y derivados de sulfamida como inhibidores de tafia UY31868A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08290520 2008-06-06

Publications (1)

Publication Number Publication Date
UY31868A true UY31868A (es) 2010-01-05

Family

ID=39800716

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31868A UY31868A (es) 2008-06-06 2009-06-04 Derivados de urea macrocíclicos y derivados de sulfamida como inhibidores de tafia

Country Status (34)

Country Link
US (5) US8580777B2 (cg-RX-API-DMAC7.html)
EP (1) EP2300462B1 (cg-RX-API-DMAC7.html)
JP (1) JP5531011B2 (cg-RX-API-DMAC7.html)
KR (1) KR101673886B1 (cg-RX-API-DMAC7.html)
CN (1) CN102056922B (cg-RX-API-DMAC7.html)
AR (1) AR072007A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009254257B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0913349A2 (cg-RX-API-DMAC7.html)
CA (1) CA2726554C (cg-RX-API-DMAC7.html)
CL (1) CL2009001358A1 (cg-RX-API-DMAC7.html)
CO (1) CO6321271A2 (cg-RX-API-DMAC7.html)
CR (1) CR11807A (cg-RX-API-DMAC7.html)
CY (1) CY1115604T1 (cg-RX-API-DMAC7.html)
DK (1) DK2300462T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2010000363A (cg-RX-API-DMAC7.html)
EC (1) ECSP10010655A (cg-RX-API-DMAC7.html)
ES (1) ES2494390T3 (cg-RX-API-DMAC7.html)
HN (1) HN2010002558A (cg-RX-API-DMAC7.html)
HR (1) HRP20140787T1 (cg-RX-API-DMAC7.html)
IL (1) IL209772A (cg-RX-API-DMAC7.html)
MA (1) MA32322B1 (cg-RX-API-DMAC7.html)
MX (1) MX2010012793A (cg-RX-API-DMAC7.html)
NI (1) NI201000203A (cg-RX-API-DMAC7.html)
NZ (1) NZ589671A (cg-RX-API-DMAC7.html)
PL (1) PL2300462T3 (cg-RX-API-DMAC7.html)
PT (1) PT2300462E (cg-RX-API-DMAC7.html)
RU (1) RU2502736C2 (cg-RX-API-DMAC7.html)
SI (1) SI2300462T1 (cg-RX-API-DMAC7.html)
SV (1) SV2010003747A (cg-RX-API-DMAC7.html)
TW (1) TWI455928B (cg-RX-API-DMAC7.html)
UA (1) UA104002C2 (cg-RX-API-DMAC7.html)
UY (1) UY31868A (cg-RX-API-DMAC7.html)
WO (1) WO2009146802A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201007719B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2494390T3 (es) 2008-06-06 2014-09-15 Sanofi Derivados macrocíclicos de urea y de sulfamida como inhibidores de TAFIa
AU2009263076B2 (en) 2008-06-23 2012-07-26 Astrazeneca Ab New heterocyclic carboxamides for use as thrombin inhibitors
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
ME02630B (me) * 2012-03-06 2017-06-20 Pfizer Makrociklički derivati, namijenjeni liječenju proliferativnih bolesti
EP3027611B1 (en) * 2013-06-10 2017-07-26 Sanofi Macrocyclic urea derivatives as inhibitors of tafi a, their preparation and their use as pharmaceuticals
UY35809A (es) * 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
CN103755852B (zh) * 2013-12-18 2015-12-09 湖北大学 线型聚苯乙烯支载(4s)-(4’-氧苄基)-2-正丁基环磺酰胺及其制备方法和用途
CN106631832A (zh) * 2016-10-08 2017-05-10 帕潘纳(北京)科技有限公司 一种氨基醚类化合物的制备方法
US10411291B2 (en) * 2017-03-22 2019-09-10 Nanotek Instruments, Inc. Multivalent metal ion battery having a cathode layer of protected graphitic carbon and manufacturing method

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU667995B2 (en) 1993-02-15 1996-04-18 Bayer Aktiengesellschaft New pseudopeptides having an antiviral action
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
US5888971A (en) * 1996-02-20 1999-03-30 Ortho Pharmaceutical Corporation, Inc. Macrocyclic peptides useful in the treatment of thrombin related disorders
CA2298601A1 (en) 1997-08-28 1999-03-11 Pharmacia & Upjohn Company Inhibitors of protein tyrosine phosphatase
US6124278A (en) * 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response
US6482921B1 (en) 1999-01-28 2002-11-19 Essential Therapeutics, Inc. Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use
DE60042585D1 (de) * 2000-02-29 2009-09-03 Univ Firenze 3-Aza-6,8-dioxabicycloÄ3.2.1Üoctane und Analoga sowie diese enthaltende kombinatorische Bibliotheken
DE102004020186A1 (de) * 2004-04-22 2005-11-17 Aventis Pharma Deutschland Gmbh Heterocyclylessigsäuren als Inhibitoren von TAFla
AU2007327959B2 (en) 2006-12-06 2013-08-01 Sanofi-Aventis Urea and sulfamide derivatives as tafia inhibitors
ES2494390T3 (es) 2008-06-06 2014-09-15 Sanofi Derivados macrocíclicos de urea y de sulfamida como inhibidores de TAFIa

Also Published As

Publication number Publication date
MX2010012793A (es) 2010-12-14
RU2010154089A (ru) 2012-07-20
US9126955B2 (en) 2015-09-08
IL209772A0 (en) 2011-02-28
KR101673886B1 (ko) 2016-11-08
DOP2010000363A (es) 2010-12-15
AU2009254257A1 (en) 2009-12-10
CA2726554A1 (en) 2009-12-10
US20140039011A1 (en) 2014-02-06
RU2502736C2 (ru) 2013-12-27
EP2300462B1 (de) 2014-05-21
US20160251324A1 (en) 2016-09-01
CN102056922B (zh) 2013-11-20
ES2494390T3 (es) 2014-09-15
US9688645B2 (en) 2017-06-27
CA2726554C (en) 2015-02-24
HN2010002558A (es) 2012-08-28
EP2300462A1 (de) 2011-03-30
AR072007A1 (es) 2010-07-28
WO2009146802A1 (de) 2009-12-10
US20110178130A1 (en) 2011-07-21
US20140206760A1 (en) 2014-07-24
US8580777B2 (en) 2013-11-12
KR20110020795A (ko) 2011-03-03
PL2300462T3 (pl) 2014-10-31
JP5531011B2 (ja) 2014-06-25
IL209772A (en) 2016-04-21
ZA201007719B (en) 2011-07-27
SI2300462T1 (sl) 2014-09-30
NZ589671A (en) 2012-03-30
TWI455928B (zh) 2014-10-11
JP2011521981A (ja) 2011-07-28
UA104002C2 (ru) 2013-12-25
ECSP10010655A (es) 2011-01-31
US20160024033A1 (en) 2016-01-28
HK1152936A1 (en) 2012-03-16
CN102056922A (zh) 2011-05-11
NI201000203A (es) 2011-09-29
CO6321271A2 (es) 2011-09-20
MA32322B1 (fr) 2011-05-02
CY1115604T1 (el) 2017-01-04
SV2010003747A (es) 2011-03-15
PT2300462E (pt) 2014-08-05
AU2009254257B2 (en) 2013-11-21
TW201008917A (en) 2010-03-01
HRP20140787T1 (hr) 2014-11-21
US8722655B2 (en) 2014-05-13
US9309207B2 (en) 2016-04-12
CL2009001358A1 (es) 2009-11-27
DK2300462T3 (da) 2014-08-18
CR11807A (es) 2011-02-16
BRPI0913349A2 (pt) 2015-11-24

Similar Documents

Publication Publication Date Title
UY31868A (es) Derivados de urea macrocíclicos y derivados de sulfamida como inhibidores de tafia
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
CO6390069A2 (es) Compuestos de piridina sustituida unida por puente a un heterociclo, como inhibidores de la vía de señalización hedgehog.
GT200900186A (es) Compuestos carboxamida y su uso como inhibidores de calpaína
CR20130024A (es) Compuestos heterocíclicos fusionados
UY32384A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
CL2011002857A1 (es) Compuestos derivados de fenil o heteroaril piridina, inhibidores de sintasa de aldosterona; composicion farmaceutica que comprende un compuesto; combinacion farmaceutica que comprende un compuesto; y uso de los compuestos en el tratamiento de enfermedades cardiovasculares.
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
CO6511220A2 (es) Quinazolinas como inhibidores de los canales iónicos de potasio
CR20110103A (es) Heteroarilos sustituidos
MX374452B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
CR20140079A (es) Aminoquinazolinas como inhibidores de quinasa
UY34216A (es) Nuevos compuestos que inhiben la actividad de la Lp-PLA2
UY32168A (es) Nuevas composiciones de compuestos heterociclicos nitrogenados antibacterianos con otros compuestos antibacterianos y su utilización como medicamentos
BRPI0510159A (pt) derivados de imidazol como inibidores de tafia
UA107671C2 (en) N1-substityted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
ECSP14011792A (es) Inhibidores de iap
GT201300041A (es) Composicion fungicida sinergista
PA8667201A1 (es) Nuevos compuestos farmaceuticos
NO20092246L (no) Urea og sulfamidderivater som tafiainhibitorer
BR112014016803A2 (pt) amidas macrocíclicas como inibidoras de protease
MX2015011567A (es) Halogeno-pirazoles como inhibidores de trombina.
BR112016002027A2 (pt) derivados de 2-benzoilaminobenzamida como inibidores de bcl-3
NI201000139A (es) ASOCIACION DE UN INHIBIDOR DE CORRIENTE SINUSAL If Y DE UN BETA-BLOQUEANTE
UY32215A (es) Inhibidores de la s1p liasa para el tratamiento de malaria cerebral

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181030